Rebecca Hawrusik, MS

Senior Research Analyst
Harvard Pilgrim Health Care Institute

Poster(s):

• (A-350) Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results From an Interim Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-333) Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-334) Incidence rates of safety outcomes in a post-approval study of the Pfizer-BioNTech monovalent COVID-19 vaccine in the United States, booster dose analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-200) Strengthening inferential studies in the U.S. FDA Sentinel initiative: Results from a methodological demonstration project
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (C-062) Utilization of hormonal contraceptives during the postpartum period in the FDA Sentinel System
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET